News

The unprecedented demand for the pediatric RSV immunization, nirsevimab-alip, has resulted in a dramatic uptake in production.

In the second installment of the RSV Roundtable, our panel explains how they are educating patients and parents when it comes to RSV, vaccines and preventive measures, and limited treatment availability.

In the news this week, the FDA approved the antifungal, isavuconazonium sulfate, which is indicated for children as young as 1 year of age; the continued clinical usefulness of doxycycline; examining infectious disease consults in gram-negative bacteremia; and a clinician utilizes mobile clinics to bring care to marginalized populations.

A study finds pathogen spores remain on surgical scrubs and patient gowns even after sodium hypochlorite disinfectant application. This finding presents an infection prevention challenge.

A comprehensive cohort study explored the impact of inactivated COVID-19 vaccines administered within 3 months before conception, revealing reassuring findings that neonatal outcomes, including preterm birth and NICU admission, remain unaffected.

Three posters presented at ASHP Midyear 2023 delved deeper into the topic of antimicrobial stewardship programs and their impact on antibiotic resistance.

The implementation of clinical and specialty pharmacy services significantly increased the rate of patients transitioning from tenofovir disoproxil fumarate to tenofovir alafenamide.

Recent studies support the argument that all positive blood cultures trigger an automatic consultation.

A clinician utilizes mobile clinics to bring a hybrid of primary and urgent care to marginalized populations and help people overcome barriers and gets them into the continuum of care.

Just 8.5% of eligible patients were screened for hepatitis C, and among them, 5.9% tested positive for HCV antibody and 3.0% had an active infection.

The older antibiotic has been shown to be effective as a preventative measure for one group of infections as well as reducing the risk of a health care-associated infection.

The approval of the antifungal, isavuconazonium sulfate (Cresemba), is indicated for children as young as 1 year of age and the approval was based from 2 clinical trials.

Last year’s historic RSV season left many wondering if this was going to become a recurring trend. Physicians weigh in on what they are seeing at their institutions in terms of infection rates.

This week's news looked at the medical and economic burden of AMR, why the implementation of new College of American Pathologists rules presents an opportunity for collaboration between microbiology labs and ID providers, which specific antibiotics showed the greatest associations with adverse drug reaction case reports related to C diff, and how infants with HIV could be spared from requiring lifetime ART if treated within hours of birth.

Ciprofloxacin, ceftriaxone, and piperacillin/tazobactam showed the greatest associations with adverse drug reaction case reports related to CDI.

Infants with HIV could be spared from requiring lifetime ART if treated within hours of birth to disrupt formation of HIV viral reservoirs.

The Manischewitz corporation issued the voluntary effort on some limited units of their dark chocolate coins and should be considered for people who have a milk allergy or are severely sensitive to it.

This bipartisan initiative highlights the need for a comprehensive approach to combat antimicrobial resistance (AMR), incorporating both antibiotic drug development and increased funding for stewardship programs.

A clinician discusses the vaccines' efficacy, which risk factors may rank higher for disease severity, and offers insights on counseling patients.

High cure rates underscore the effectiveness of the No One Waits (NOW) model in ensuring not only treatment initiation but also successful completion, ultimately reducing the burden of HCV in the studied population and possibly beyond.

As of last Friday, 117 people have been sickened, 61 hospitalized, and 2 people have died.

Amikacin inhaled once daily for 3 days reduced risk of developing ventilator-associated pneumonia in placebo-controlled trial in critically ill.

A study offers a glimpse into what populations may be more likely to suffer a prolonged infection and may need to be prospectively followed for surveillance and monitoring.

The emergency use listing (EUL) now provides another option for those who are in World Health Organization (WHO) member states.

This week's news includes a Massachusetts hospital facing a lawsuit for potential HIV and hepatitis exposure, a study shows reduced mortality rates in combining vancomycin and cefazolin in patients with bloodstream infections, a PCR-based rapid test can de-escalate antibiotic therapy quicker for bloodstream infections, and how the implementation of new College of American Pathologists rules presents an opportunity for collaboration between clinical microbiology laboratories and infectious disease pharmacists and physicians.

Therapy development, management improvements, and public health initiatives have all helped to change the trajectory of health outcomes for many, but still millions of people remain behind and are not in the continuum of care.

Salem Hospital faces a class action lawsuit over potential hepatitis and HIV exposure to hundreds of patients. The lawsuit alleges negligence and emotional distress, with the hospital claiming a minimal infection risk.

A recent novel study found reduced mortality rates in combining these therapies in patients being treated for this specific bacteremia.